Table 4.

Selected clinical trials, active or in development, with blinatumomab (Blin) in de novo or R/R pediatric and adult ALL.¹

ClinicalTrials.gov identifier	Schedule	Planned n pts	Age	Status
De novo ALL, Ph-positive
NCT03263572	Blin and ponatinib	60	⩾60	Active
NCT02744768	Dasatinib, prednisone and Blin	80	⩾18	Active
NCT02143414	Blin and CHT or Blin and dasatinib	44	⩾65	Active
De novo ALL. Ph-negative
NCT02877303	Blin and HyperCVAD	60	⩾14	Active
NCT02458014	Blin in MRD-positive ALL	40	⩾18	Active
NCT03109093	Blin in MRD-positive ALL	60	⩾18	Active
NCT03541083	Blin prephase and CHT	80	18–70	Active
NCT03480438	Blin and CHT	50	56–74	In preparation
NCT03523429	CHT and Blin in consolidation in HR ALL	38	18–55	Active
NCT03709719	Blin in HR ALL	95	18–59	Active
NCT03643276	CHT and Blin in consolidation (randomized)	5000	<18	Active
NCT02003222	CHT versus Blin in consolidation	509	30–70	Active
NCT03367299	Sequential CHT and Blin	149	18–65	Active
NCT03117751	CHT and Blin or others	1000	<18	Active
NCT03114865	Blin maintenance after alloHSCT	12	⩾18	Active
NCT03751709	Blin and haploidentical HSCT	10	⩾18	Active
NCT02807883	Blin maintenance after alloHSCT	30	18–70	Active
NCT02877303	Blin and inotuzumab	64	⩾18	Active, also for R/R ALL
NCT01371630	CHT, inotuzumab followed by Blin	256	56–74	Active
Relapsed/refractory ALL
NCT03518112	CHT and Blin	44	⩾18	Active
NCT02101853	CHT versus Blin (randomized)	598	1–30	Active
NCT02393859	CHT versus Bin (randomized)	202	<18	Active
NCT02997761	Blin and ibrutinib	20	⩾18	Active
NCT03628053	Blin or inotuzumab versus tisagenlecleucel	220	⩾18	In preparation
NCT03160079	Blin and pembrolizumab	24	⩾18	Active
NCT02879695	Blin and nivolumab w/o ipilimumab	30	⩾16	Active

¹ClinicalTrials.gov, accessed 15 October 2019.

ALL, acute lymphoblastic leukemia; alloHSCT, allogeneic hematopoietic stem cell transplantation; Blin, blinatumomab; CHT, chemotherapy; HR ALL, high-risk ALL; NCT, National Clinical Trial; pts, patients; R/R, relapsed/refractory; w/o, with/without.